Table 4 Controlled ovarian stimulation cycles of the study patients
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |||||
|---|---|---|---|---|---|---|---|---|---|
AFC | 9 | 15 | 15 | 14 | 32 | ||||
AMH (ng/ml) | 3.19 | 9.06 | 2.52 | 2.69 | 13.35 | ||||
Ovarian stimulation | May 2014 | August 2017 | June 2017 | November 2017 | February 2019 | April 2019 | April 2019 | July 2019 | September 2019 |
COS protocol | Luteal-phase GnRH-a long protocol | Follicular-phase GnRH-a long protocol | GnRH antagonist | Luteal-phase GnRH-a long protocol | PPOS | PPOS | Luteal phase stimulation | PPOS | Follicular-phase GnRH-a long protocol |
LH suppression | Triptorelin 1.25 mg | Leuprorelin 3.75 mg | Ganirelix 0.25 mg/d | Triptorelin 1.87 mg | MPA 12 mg/d, Cetrotide 0.25 mg/d | MPA 12 mg/d | None | Femostone 4 mg/d, MPA 12 mg/d | Leuprorelin 3.75 mg |
Glucocorticoid | None | DXM 0.75 mg/d | DXM 0.375 mg/d | DXM 0.375 mg/d | DXM 0.75 mg/d | DXM 0.75 mg/d | DXM 0.75 mg/d | DXM 0.75 mg/d | DXM 0.75 mg/d |
E2 on initiation day, ng/L | < 20 | < 20 | 26 | < 20 | < 20 | 28 | < 20 | < 20 | < 20 |
P on initiation day, ng/ml | 8.44 | 6.17 | 0.41 | 1.19 | 0.46 | 3.02 | 4.71 | 0.45 | 0.12 |
Duration of stimulation, days | 15 | 11 | 11 | 12 | 9 | None | 9 | 10 | 9 |
Total gonadotropin dose, IU | 4125 | 1650 | 3100 | 3600 | 1050 | None | 1500 | 3300 | 1200 |
Follicles ≥ 14 mm on HCG day | 12 | 7 | 10 | 18 | 3 | 1 | 5 | 6 | 13 |
E2 on HCG day, ng/L | 296 | 57 | 636 | 518 | 43 | < 20 | 46 | 55 | 106 |
P on HCG day, ng/ml | 17.37 | 6.23 | 3.43 | 8.31 | 5.56 | 2.31 | 15.36 | 5.92 | 6.25 |
Endometrial thickness on HCG day, mm | 4.8 | 6.0 | 9.1 | 8.0 | 6.2 | 6.6 | 5.7 | 7.3 | 2.6 |
Number of retrieved oocytes | 12 | 9 | 11 | 16 | 3 | 1 | 5 | 8 | 15 |
Number of available embryos | 5 | 5 | 2 | 2 | 1 | 0 | 2 | 2 | 7 |